PCI Pharma Services
Global contract development and manufacturing organization (CDMO) with 38 sites across North America, Europe, and Asia-Pacific offering integrated drug development, manufacturing, and packaging services from early-stage to commercial scale.
Why interesting to a deal team
Kohlberg's co-led 2025 strategic investment signals consolidation appetite; Bain Capital partnership indicates growth-phase CDMO with scaling economics; Haffar's CEO tenure shows proven CDMO transformation leadership.
Experts connected to this company
- Salim HaffarChief Executive Officer since 2018, led global CDMO transformation
- Andrew KaplanBain Capital partner leading 2025 strategic CDMO investment
- Christina DixCo-led 2025 Bain Capital strategic growth investment
Salim Haffar
Chief Executive Officer
PCI Pharma Services
As CEO since 2018, Haffar tripled PCI's revenue and led it through three PE ownership transitions, making him the key contact for CDMO diligence or sponsor conversations.
Andrew Kaplan
Partner, Healthcare
Bain Capital
Kaplan is a lead Bain Capital healthcare dealmaker actively deploying capital into pharma services/CDMO platforms like PCI Pharma, making him a key read on deal terms and sector appetite.
Christina Dix
Partner, European Private Equity Healthcare
Bain Capital
Co-heads Bain Capital's European healthcare practice and is actively deploying capital into pharma services and CDMO assets like PCI Pharma and FIS.
Sources
- No name matchPrimaryArchived 2026-01-20pci.com/global-cdmo-company/global-cdmo-north-america
- Page titlePressArchived 2025-07-14businesswire.com/news/home/20250714606219/en/PCI-Pharma-Services-Enters-Next-Phase-of-Growth-With-Strategic-Investment-from-Bain-Capital-Kohlberg-and-Mubadala
- Structured dataPrimaryArchived 2026-01-21pci.com